至 2035 年患者來源異種移植模型市場分析和預測：按類型、產品、服務、技術、應用、最終用戶和鼠模型分類。

全球患者來源異種移植（PDX）模型市場預計將從2025年的4億美元成長到2035年的11億美元，複合年成長率（CAGR）為12.1%。政府和私人機構對癌症研究投入的增加正在加速PDX模型在全球的應用。 2024年10月，英國國家健康研究所（NIHR）和生命科學辦公室（OLS）投資1,401萬美元，用於支持包括PDX在內的先進臨床前模型的六個癌症研究計畫。同樣，中國也在增加對免疫腫瘤學的投資，利用PDX模型研究腫瘤與免疫系統的相互作用，並開發CAR-T療法。生物技術和製藥行業的成長也進一步推動了市場需求。 2025年10月，日本國立癌症中心推出了“J-PDX庫”，旨在加強轉化腫瘤學研究和精準醫療主導的藥物舉措。

臨床前研究中的腫瘤類型涵蓋了多種惡性腫瘤，旨在了解疾病進展和治療反應。消化器官系統腫瘤有助於深入了解大腸直腸癌和胃癌，婦科腫瘤則專注於卵巢癌和子宮癌。呼吸系統腫瘤包括肺癌模型，中樞神經系統腫瘤則以膠質母細胞瘤及相關腦瘤為研究對象。骨髓惡性腫瘤包括白血病和淋巴瘤，皮膚腫瘤則研究黑色素瘤等皮膚癌。其他固態腫瘤則代表了未包含在上述類別中的多種癌症。結合這些分類，研究人員能夠模擬人類疾病的生物學特徵，並評估針對多種癌症適應症的新治療方法。

動物模型是腫瘤學研究中不可或缺的工具，它們為研究腫瘤生物學和治療性介入提供了可控的系統。小鼠模型因其易於進行基因操作、繁殖週期短以及可獲得免疫力缺乏品系（從而能夠進行人類腫瘤的異種移植）而被廣泛應用。體型較大的大鼠模型則提供了互補的視角，能夠進行更複雜的外科手術和藥理研究。這兩種模型均可作為藥物療效測試、生物標記發現和轉化研究的平台。這些模型的使用彌合了體外實驗和臨床試驗之間的鴻溝，確保候選治療方法在進入人體試驗之前能夠進行體內評估。

區域概覽

預計到2025年，北美將引領病患來源異種移植（PDX）模型市場，佔48.2%的市佔率。這主要得益於癌症發病率的上升以及對可預測的、與患者相關的臨床前模型日益成長的需求。該地區強大的研究基礎設施和高額的醫療費用支出也進一步推動了市場成長。預計到2024年，美國將新增約2,001,140例癌症病例和611,720例死亡病例，創歷史新高。這一成長歸因於人口老化、診斷能力的提高以及篩檢的增加，所有這些因素都推動了對PDX等先進腫瘤研究模型的需求，以促進有效的藥物研發和精準醫療。

亞太地區是患者來源異質骨移植（PDX）模型市場成長最快的地區，預計在預測期內將以14.8%的複合年成長率成長。這一成長主要得益於全部區域癌症負擔的不斷加重以及腫瘤研究能力的不斷提升。根據輝瑞公司統計，亞洲主要國家約有360萬癌症患者，其中女性患者約400萬，光是中國就有160萬男性和150萬女性患者。在中國，已建立了涵蓋胃腸道癌、肺癌、肝癌和食道癌的大規模PDX模型庫，保留了腫瘤的組織學特徵和藥物反應，從而支持了先進的臨床前研究、精準醫療和加速抗癌藥物的研發。

主要趨勢和促進因素

利用 CRISPR 技術擴大人源化 PDX 模型的應用

利用CRISPR技術建構人源化患者來源異種移植（PDX）模型正日益成為全球市場的重要趨勢，其驅動力源自於免疫腫瘤學和標靶治療研究中對臨床相關平台的需求。這些先進的模型將患者腫瘤組織與人源化免疫系統結合，從而能夠更準確地評估治療反應。產業公司正在加速基因編輯PDX平台的商業化，以增強其服務能力。例如，百奧賽圖製藥公司（Biocytogen Pharmaceuticals）正在擴展其BioMice®平台，利用精準的基因編輯技術開發基因修飾和免疫人源化小鼠模型，從而提高其在腫瘤學研發和免疫療法開發中模擬人類生理和病理條件的能力。

PDX模型外包給CRO的趨勢日益明顯，正在加速市場擴張。

隨著製藥和生物技術公司越來越依賴外部合作夥伴進行專業的臨床前腫瘤學研究，將患者來源的異種移植（PDX）模型外包給合約研究組織（CRO）的做法日益增多，加速了市場擴張。不斷擴充的藥物研發管線和有限的內部資源促使贊助公司轉向擁有先進PDX專業知識的CRO。外包服務能夠提供專業的設施、技術能力和可擴展的動物飼養設施，同時降低營運成本並縮短轉化研究週期。例如，InnoSer利用PDX小鼠模型提供全面的腫瘤學CRO服務，使贊助公司能夠在體內精確複製腫瘤異質性和治療反應，從而評估治療效果並支持高效的藥物開發流程。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

• 宏觀經濟分析
• 市場趨勢
• 市場促進因素
• 市場機遇
• 市場限制因素
• 複合年均成長率：成長分析
• 影響分析
• 新興科技的發展趨勢
• 技術藍圖
• 戰略框架

第4章：細分市場分析

• 市場規模及預測：依類型
  • 胃腸道腫瘤
  • 婦科腫瘤學
  • 呼吸系統腫瘤
  • 中樞神經系統腫瘤
  • 骨髓惡性腫瘤
  • 皮膚腫瘤
  • 其他固態腫瘤
• 市場規模及預測：依產品分類
  • 小鼠模型
  • 大鼠模型
• 市場規模及預測：按滑鼠模型
  • 裸體（無心境）
  • NOD/SCID
  • NSG
  • 人源化小鼠
• 市場規模及預測：依服務分類
  • 模型建構與擴充
  • 模型特點
  • 冷凍保存
  • 其他服務
• 市場規模及預測：依應用領域分類
  • 臨床前研究
  • 生物標記分析
  • 轉化研究
  • 生物銀行
• 市場規模及預測：依最終用戶分類
  • 製藥和生物技術公司
  • CRO/CDMO
  • 大學和研究機構
• 市場規模及預測：依技術分類
  • 異位（皮下）移植
  • 原位移植

第5章 區域分析

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲
• 亞太地區
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲
  • 台灣
  • 亞太其他地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲國家
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 其他中東和非洲地區

第6章 市場策略

• 供需差距分析
• 貿易和物流限制
• 價格、成本和利潤率趨勢
• 市場滲透率
• 消費者分析
• 監管概述

第7章 競爭訊息

• 市場定位
• 市場占有率
• 競爭基準
• 主要企業的策略

第8章：公司簡介

• Charles River Laboratories
• Crown Bioscience
• The Jackson Laboratory（JAX）
• Champions Oncology
• Medicilon
• TheraIndx Lifesciences Pvt. Ltd
• Noble Life Sciences Inc
• Creative Biolabs Inc
• BioDuro
• EPO Berlin-Buch GmbH
• WuXi AppTec
• XenTech
• Urosphere
• Oncodesign Services
• Pharmatest Services
• Inotiv
• GemPharmatech
• Altogen Biosystems
• Abnova Corporation
• Taconic Biosciences

第9章 關於我們

The global Patient-Derived Xenograft (PDX) Model Market is projected to grow from $0.4 billion in 2025 to $1.1 billion by 2035, at a compound annual growth rate (CAGR) of 12.1%. Rising government and private funding for cancer research is accelerating the adoption of Patient-Derived Xenograft (PDX) models globally. In October 2024, the UK National Institute for Health Research (NIHR) and the Office for Life Sciences (OLS) invested USD 14.01 million in six cancer research projects supporting advanced preclinical models, including PDX. Similarly, China is expanding investments in immuno-oncology, leveraging PDX models for tumor-immune interaction studies and CAR-T development. Growth in biotechnology and pharmaceutical sectors further drives demand. In October 2025, Japan's National Cancer Center launched the J-PDX Library, strengthening translational oncology research and precision medicine-driven drug development initiatives.

Tumor types in preclinical research encompass a wide range of malignancies studied to understand disease progression and therapeutic response. Gastro-intestinal tumors provide insights into colorectal and gastric cancers, while gynecological tumors focus on ovarian and uterine malignancies. Respiratory tumors include lung cancer models, and central nervous system tumors address glioblastoma and related brain cancers. Hematological malignancies cover leukemias and lymphomas, whereas dermatological tumors explore skin cancers such as melanoma. Other solid tumors represent diverse cancers outside these categories. Together, these classifications enable researchers to replicate human disease biology and evaluate novel therapies across multiple cancer indications.

Animal models are essential tools in oncology research, providing controlled systems to study tumor biology and therapeutic interventions. Mice models are widely used due to their genetic manipulability, short reproductive cycles, and availability of immunodeficient strains that support human tumor xenografts. Rat models, larger in size, allow for more complex surgical procedures and pharmacological studies, offering complementary insights. Both models serve as platforms for drug efficacy testing, biomarker discovery, and translational research. Their use bridges the gap between in vitro experiments and clinical trials, ensuring that candidate therapies are evaluated in living systems before advancing to human studies.

Geographical Overview

North America dominated the Patient-Derived Xenograft (PDX) model market with a 48.2% share in 2025, driven by the rising cancer burden and increasing demand for predictive, patient-relevant preclinical models. The region's strong research infrastructure and high healthcare spending further support market expansion. In 2024, the United States is projected to record approximately 2,001,140 new cancer cases and 611,720 deaths, marking a record-high incidence. This growth is attributed to population aging, improved diagnostic capabilities, and wider screening adoption, all of which are intensifying the need for advanced oncology research models like PDX for effective drug development and precision medicine.

Asia-Pacific is the fastest-growing region in the Patient-Derived Xenograft (PDX) model market, with a CAGR of 14.8% during the forecast period. Growth is driven by a high and rising cancer burden alongside expanding oncology research capabilities across the region. According to Pfizer, major Asian countries account for approximately 3.6 million male and 4.0 million female cancer patients, with China alone representing 1.6 million males and 1.5 million females. China has developed extensive PDX libraries covering gastrointestinal, lung, liver, and esophageal cancers, preserving tumor histology and drug response, thereby supporting advanced preclinical research, precision medicine, and accelerated oncology drug development.

Key Trends and Drivers

Rising Adoption of CRISPR-Engineered Humanized PDX Models

Rising adoption of CRISPR-engineered humanized Patient-Derived Xenograft (PDX) models is emerging as a key trend in the global market, driven by the need for more translationally relevant platforms in immuno-oncology and targeted therapy research. These advanced models combine patient tumor tissues with humanized immune systems, enabling more accurate evaluation of therapeutic responses. Industry players are increasingly commercializing gene-edited PDX platforms to strengthen their offerings. For instance, Biocytogen Pharmaceuticals has expanded its BioMice(R) platform with genetically engineered and immune-humanized mouse models developed using precise gene editing, enhancing the ability to replicate human physiological and pathological conditions for oncology research and immunotherapy development.

Rising Outsourcing of PDX Models to CROs Accelerates Market Expansion

Rising outsourcing of Patient-Derived Xenograft (PDX) models to contract research organizations (CROs) is accelerating market expansion, as pharmaceutical and biotechnology companies increasingly rely on external partners for specialized preclinical oncology research. Expanding drug pipelines and limited in-house capacities are driving sponsors toward CROs with advanced PDX expertise. Outsourcing enables access to specialized infrastructure, technical capabilities, and scalable vivarium facilities, while reducing operational costs and accelerating translational timelines. For instance, InnoSer offers comprehensive oncology CRO services with PDX mouse models that allow sponsors to evaluate therapeutic efficacy by accurately replicating tumor heterogeneity and treatment responses in vivo, supporting efficient drug development processes.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Strategic Recommendations
• 1.5 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Mice Model
• 2.4 Key Market Highlights by Services
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Technology

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Technologies Landscape
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTLE Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Gastro-Intestinal Tumors
  • 4.1.2 Gynecological Tumors
  • 4.1.3 Respiratory Tumors
  • 4.1.4 Central Nervous System Tumors
  • 4.1.5 Hematological Malignancies
  • 4.1.6 Dermatological Tumors
  • 4.1.7 Other Solid Tumors
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Mice Models
  • 4.2.2 Rat Models
• 4.3 Market Size & Forecast by Mice Model (2020-2035)
  • 4.3.1 Nude (Athymic)
  • 4.3.2 NOD/SCID
  • 4.3.3 NSG
  • 4.3.4 Humanized Mice
• 4.4 Market Size & Forecast by Services (2020-2035)
  • 4.4.1 Model Creation & Expansion
  • 4.4.2 Model Characterization
  • 4.4.3 Cryopreservation
  • 4.4.4 Other Services
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Preclinical Research
  • 4.5.2 Biomarker Analysis
  • 4.5.3 Translational Research
  • 4.5.4 Biobanking
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Pharma & Biotechnology Companies
  • 4.6.2 CROs & CDMOs
  • 4.6.3 Academics & Research Institutes
• 4.7 Market Size & Forecast by Technology (2020-2035)
  • 4.7.1 Heterotopic (Subcutaneous) Implantation
  • 4.7.2 Orthotopic Implantation

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Mice Model
    • 5.2.1.4 Services
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Technology
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Mice Model
    • 5.2.2.4 Services
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Technology
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Mice Model
    • 5.2.3.4 Services
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Technology
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Mice Model
    • 5.3.1.4 Services
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Technology
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Mice Model
    • 5.3.2.4 Services
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Technology
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Mice Model
    • 5.3.3.4 Services
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Technology
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Mice Model
    • 5.4.1.4 Services
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Technology
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Mice Model
    • 5.4.2.4 Services
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Technology
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Mice Model
    • 5.4.3.4 Services
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Technology
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Mice Model
    • 5.4.4.4 Services
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Technology
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Mice Model
    • 5.4.5.4 Services
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Technology
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Mice Model
    • 5.4.6.4 Services
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Technology
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Mice Model
    • 5.4.7.4 Services
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Technology
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Mice Model
    • 5.5.1.4 Services
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Technology
  • 5.5.2 United Kingdom
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Mice Model
    • 5.5.2.4 Services
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Technology
  • 5.5.3 France
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Mice Model
    • 5.5.3.4 Services
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Technology
  • 5.5.4 Italy
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Mice Model
    • 5.5.4.4 Services
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Technology
  • 5.5.5 Spain
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Mice Model
    • 5.5.5.4 Services
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Technology
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Mice Model
    • 5.5.6.4 Services
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Technology
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Mice Model
    • 5.6.1.4 Services
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Technology
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Mice Model
    • 5.6.2.4 Services
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Technology
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Mice Model
    • 5.6.3.4 Services
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Technology
  • 5.6.4 Rest of MEA
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Mice Model
    • 5.6.4.4 Services
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Technology

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Charles River Laboratories
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Crown Bioscience
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 The Jackson Laboratory (JAX)
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Champions Oncology
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Medicilon
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 TheraIndx Lifesciences Pvt. Ltd
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Noble Life Sciences Inc
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Creative Biolabs Inc
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 BioDuro
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 EPO Berlin-Buch GmbH
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 WuXi AppTec
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 XenTech
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Urosphere
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Oncodesign Services
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Pharmatest Services
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Inotiv
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 GemPharmatech
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Altogen Biosystems
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Abnova Corporation
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Taconic Biosciences
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us